Zimmer Biomet Holdings, Inc. $ZBH Stock Position Trimmed by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC cut its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 19,841 shares of the medical equipment provider’s stock after selling 537 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Zimmer Biomet were worth $1,810,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of ZBH. Brighton Jones LLC bought a new stake in Zimmer Biomet in the 4th quarter valued at about $204,000. GAMMA Investing LLC lifted its position in Zimmer Biomet by 52.4% in the 1st quarter. GAMMA Investing LLC now owns 3,502 shares of the medical equipment provider’s stock valued at $396,000 after purchasing an additional 1,204 shares during the last quarter. Golden State Wealth Management LLC lifted its position in Zimmer Biomet by 103.0% in the 1st quarter. Golden State Wealth Management LLC now owns 1,411 shares of the medical equipment provider’s stock valued at $160,000 after purchasing an additional 716 shares during the last quarter. Diversified Trust Co bought a new stake in Zimmer Biomet in the 1st quarter valued at about $228,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Zimmer Biomet by 12.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,941 shares of the medical equipment provider’s stock valued at $2,800,000 after buying an additional 2,785 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BTIG Research raised their target price on shares of Zimmer Biomet from $118.00 to $122.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Evercore ISI lowered their target price on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 7th. Rothschild Redb raised shares of Zimmer Biomet to a “strong-buy” rating in a research note on Thursday, September 18th. Raymond James Financial raised their target price on shares of Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Rothschild & Co Redburn assumed coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They set a “buy” rating and a $130.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and an average target price of $111.94.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $103.14 on Monday. The firm’s 50 day moving average is $101.86 and its 200-day moving average is $97.64. The stock has a market capitalization of $20.43 billion, a P/E ratio of 25.09, a P/E/G ratio of 2.37 and a beta of 0.67. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 12-month low of $89.22 and a 12-month high of $114.72.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analysts’ expectations of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.01 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is currently 23.36%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 0.70% of the stock is owned by corporate insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.